The Cooper Companies, Inc. $COO Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 13.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 9,800 shares of the medical device company’s stock after selling 1,548 shares during the period. Candriam S.C.A.’s holdings in Cooper Companies were worth $697,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Cooper Companies by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock worth $368,893,000 after acquiring an additional 127,907 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Cooper Companies by 3.4% during the 1st quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock worth $436,681,000 after acquiring an additional 172,485 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Cooper Companies by 17.0% in the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after buying an additional 686,751 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Cooper Companies by 12.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company’s stock valued at $333,595,000 after buying an additional 425,400 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of Cooper Companies by 36.0% during the 1st quarter. Millennium Management LLC now owns 2,577,416 shares of the medical device company’s stock worth $217,405,000 after buying an additional 682,166 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Lawrence Erik Kurzius acquired 2,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the acquisition, the director owned 5,777 shares of the company’s stock, valued at $395,089.03. This trade represents a 52.95% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel G. Mcbride acquired 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average price of $65.04 per share, with a total value of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares of the company’s stock, valued at $4,105,324.80. The trade was a 4.99% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 17,975 shares of company stock worth $1,216,346. Insiders own 1.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on COO shares. Barclays started coverage on shares of Cooper Companies in a report on Monday, October 13th. They issued an “overweight” rating and a $85.00 price target for the company. BNP Paribas raised shares of Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. BNP Paribas Exane raised shares of Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Tuesday, July 22nd. Robert W. Baird lowered their price objective on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. Finally, Piper Sandler reduced their target price on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Trading Down 1.1%

COO opened at $71.35 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The company’s 50 day simple moving average is $69.75 and its two-hundred day simple moving average is $72.16. The firm has a market capitalization of $14.19 billion, a price-to-earnings ratio of 35.15, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $106.63.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has approved a share repurchase plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.